Company intelligence / Profile preview

ViSci Ltd.

Ownership: Private
Development stage: Phase 2

Overview

Completed a Phase 1/2 clinical trial (NCT02129673) evaluating the safety and ocular hypotensive efficacy of VS101 Subconjunctival Latanoprost Insert in patients with open-angle glaucoma or ocular hypertension. The trial compared a slow-release formulation of latanoprost with topically administered commercially available latanoprost.

Therapeutic areas: Ophthalmology
Modalities: Controlled-release drug delivery systems
Industry: Biotech

Drug pipeline

1 asset

Eye-D

Unknown

Partnerships

Aerie Pharmaceuticals, Inc. (through Novaer LLC)

Beyond the preview

Go deeper on ViSci Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViSci Ltd..

Explore the full profile